Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced ascarid infections in dogs

Table 1 Design of studies conducted to evaluate the efficacy of an oral chewable tablet containing sarolaner, moxidectin and pyrantel pamoate against induced ascarid infections in dogs

Study	Ascarid/Target stage (isolate origin)	Treatment group^a	n	Day of treatment	Day of inoculation^b	Day(s) of fecal egg counts	Day of worm recovery
1	Toxocara canis/immature adults (L₅) (USA)	Placebo	8	0	− 24	na	7
		SAR + MOX + PYR	8
		SAR + MOX	8
2	Toxocara canis/immature adults (L₅) (EU)	Placebo	8	0	− 24	na	7
2	Toxocara canis/immature adults (L₅) (EU)	SAR + MOX + PYR	8	0	− 24	na	7
3	Toxocara canis/adults (USA)	Placebo	8	0	− 49	− 3	7
		SAR + MOX + PYR	8
		SAR	8
		MOX	8
		PYR	8
4	Toxocara canis/adults (EU)	Placebo	8	0	− 57	− 8, − 6, − 4, − 3	7
4	Toxocara canis/adults (EU)	SAR + MOX + PYR	8	0	− 57	− 8, − 6, − 4, − 3	7
5	Toxascaris leonina/adults (EU)	Placebo	8	0	− 88	− 8, − 6, − 4, − 3	7
5	Toxascaris leonina/adults (EU)	SAR + MOX + PYR	8	0	− 88	− 8, − 6, − 4, − 3	7
6	Toxascaris leonina/adults (EU)	Placebo	8	0	− 88	− 8, − 6, − 4, − 3	10
6	Toxascaris leonina/adults (EU)	SAR + MOX + PYR	8	0	− 88	− 8, − 6, − 4, − 3	10

^aSingle oral administration providing minimum dosages of 1.2 mg/kg sarolaner (SAR), 24 µg/kg moxidectin (MOX) and 5 mg/kg pyrantel pamoate (PYR)
^bEach dog inoculated with L₃ larvated T. canis or T. leonina eggs. In Studies 1, 2, 5 and 6 each dog was inoculated with 300 ± 50 eggs, and in Studies 3 and 4 each dog was inoculated with 250–300 (± 50) eggs
Abbreviations: USA, United States of America; EU, Europe; na, not applicable

ISSN: 1756-3305